BRPI0316384B8 - imunoensaio não competitivo para analitos pequenos - Google Patents

imunoensaio não competitivo para analitos pequenos

Info

Publication number
BRPI0316384B8
BRPI0316384B8 BRPI0316384A BR0316384A BRPI0316384B8 BR PI0316384 B8 BRPI0316384 B8 BR PI0316384B8 BR PI0316384 A BRPI0316384 A BR PI0316384A BR 0316384 A BR0316384 A BR 0316384A BR PI0316384 B8 BRPI0316384 B8 BR PI0316384B8
Authority
BR
Brazil
Prior art keywords
analyte
competitive immunoassay
small analytes
binding partner
binding
Prior art date
Application number
BRPI0316384A
Other languages
English (en)
Other versions
BRPI0316384B1 (pt
BR0316384A (pt
Inventor
Matti Höyhtyä
Timo Pulli
Hans SÖDERLUND
Kristiina Takkinen
Original Assignee
Valtion Teknillinen Tutkimuskeskus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8564953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0316384(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valtion Teknillinen Tutkimuskeskus filed Critical Valtion Teknillinen Tutkimuskeskus
Publication of BR0316384A publication Critical patent/BR0316384A/pt
Publication of BRPI0316384B1 publication Critical patent/BRPI0316384B1/pt
Publication of BRPI0316384B8 publication Critical patent/BRPI0316384B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format
    • G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"imunoensaio não competitivo para analitos pequenos". a invenção refere-se a um imunoensaio não competitivo para analitos pequenos, em que o analito é reagido com dois parceiros ligantes. o primeiro parceiro ligante se liga ao analito para formar um complexo entre o primeiro parceiro ligante e o analito, e o segundo parceiro ligante se liga ao complexo formado pelo primeiro parceiro ligante e o analito. o complexo resultante formado entre o analito e os parceiros ligantes é detectado. os parceiros ligantes são proteínas, tais como anticorpos incluindo fragmentos de anticorpo. a invenção refere-se ainda a pares reativos e kits de teste úteis nos ensaios, bem como ao uso dos pares reativos e a um processo para sua preparação. novos reagentes e meios para sua preparação são também providos.
BRPI0316384A 2002-11-18 2003-11-17 imunoensaio não competitivo para analitos pequenos BRPI0316384B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20022048A FI20022048A0 (fi) 2002-11-18 2002-11-18 Ei-kompetetiivinen immunomääritys pienille analyyteille
PCT/FI2003/000875 WO2004046733A1 (en) 2002-11-18 2003-11-17 Non-competitive immunoassay for small analytes

Publications (3)

Publication Number Publication Date
BR0316384A BR0316384A (pt) 2005-10-04
BRPI0316384B1 BRPI0316384B1 (pt) 2016-07-05
BRPI0316384B8 true BRPI0316384B8 (pt) 2021-07-27

Family

ID=8564953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0316384A BRPI0316384B8 (pt) 2002-11-18 2003-11-17 imunoensaio não competitivo para analitos pequenos

Country Status (17)

Country Link
US (1) US7749712B2 (pt)
EP (1) EP1579222B8 (pt)
JP (1) JP4729701B2 (pt)
CN (1) CN1711476B (pt)
AT (1) ATE408146T1 (pt)
BR (1) BRPI0316384B8 (pt)
CA (1) CA2503509C (pt)
DE (1) DE60323538D1 (pt)
DK (1) DK1579222T3 (pt)
EA (1) EA200500643A1 (pt)
ES (1) ES2312828T3 (pt)
FI (1) FI20022048A0 (pt)
MX (1) MXPA05005288A (pt)
NO (1) NO338417B1 (pt)
NZ (1) NZ539714A (pt)
WO (1) WO2004046733A1 (pt)
ZA (1) ZA200503475B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109067A1 (en) 2001-12-06 2003-06-12 Immunetech, Inc. Homogeneous immunoassays for multiple allergens
JP2007040834A (ja) * 2005-08-03 2007-02-15 Japan Science & Technology Agency 免疫測定用試薬
FI20075251A0 (fi) * 2007-04-13 2007-04-13 Hytest Oy Immunomääritys epästabiilien antigeenien määrittämiseksi
GB0707870D0 (en) * 2007-04-23 2007-05-30 Selected Antibodies Ltd Assay Devices and Methods and Components for use Therein
ATE522816T1 (de) * 2007-12-18 2011-09-15 Inst Nat Sante Rech Med Endogenes morphin oder natürlich vorkommender metabolit davon als marker für sepsis
GB0725234D0 (en) * 2007-12-24 2008-02-06 Oxtex Ltd Electrochemical assays
CA2719036A1 (en) * 2008-04-02 2009-10-08 Vivacta Ltd A method for sensing a chemical
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
FI20085579A0 (fi) * 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
DE102008049601A1 (de) * 2008-09-30 2010-04-01 Siemens Healthcare Diagnostics Products Gmbh Antikörper zur Bestimmung des Prothrombin-Fragments F2/F1+2 in einem homogenen Immunoassay
MY151976A (en) * 2009-07-21 2014-07-31 Sekisui Medical Co Ltd Insulin assay
IN2012DN03824A (pt) * 2009-10-30 2015-08-28 Merck Sharp & Dohme
CA2780845C (en) * 2009-11-19 2014-12-30 Proteinexpress Co., Ltd. Fluoroimmunoassay method
US8883978B2 (en) 2010-05-11 2014-11-11 Institute For Cancer Research Antibodies to tumor endothelial marker 7R
BR112014006405A2 (pt) * 2011-09-21 2017-04-04 Fujirebio Kk anticorpo, conjunto, e, método para medir um complexo de afinidade
EP2769219B1 (en) * 2011-10-21 2017-08-30 Decimadx LLC Point-of care immunoassay for quantitative small analyte detection
EP2637021A1 (de) 2012-03-06 2013-09-11 Securetec Detektions-Systeme AG Verfahren und Vorrichtung zum Nachweis von Analyten
US9804161B1 (en) * 2012-05-14 2017-10-31 Lawrence Livermore National Security, Llc Detector and related, devices, methods and systems
EP2722669A1 (de) 2012-10-22 2014-04-23 Securetec Detektions-Systeme AG Verfahren und Vorrichtung zum Nachweis von illegalen Drogen
US10307446B2 (en) 2014-03-21 2019-06-04 St&T International, Inc. Cannabis extraction method and compositions
FI126746B (en) 2014-04-07 2017-05-15 Teknologian Tutkimuskeskus Vtt Oy Antibody to HT-2 Toxin-HT-2 Toxin Antibody Complex
US11001872B2 (en) * 2015-09-22 2021-05-11 Shawn Clark Designing customized protein-specific buffer system
HK1258313A1 (zh) 2015-10-23 2019-11-08 Fred Hutchinson Cancer Center 建立化学诱导的二聚化蛋白体系以调节细胞事件的方法
CN108779169B (zh) * 2015-12-21 2022-06-07 图尔库大学 针对包含蓝细菌环肽肝毒素的免疫复合物的抗体
JP2019507890A (ja) * 2016-01-22 2019-03-22 アフィメディックス， インコーポレイテッド ビタミンｄ代謝産物の検出のためのデバイス
AU2017301763B2 (en) * 2016-07-29 2023-07-06 Diazyme Laboratories, Inc. Methods and compositions for assaying vitamin D
CN118440202A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
CN116963779A (zh) 2020-09-02 2023-10-27 国立大学法人东京大学 癌症免疫微环境的调节物质及其预防、诊断或治疗
WO2023102201A2 (en) * 2021-12-03 2023-06-08 University Of Utah Research Foundation High selective cd229 antigen binding domains and methods of use
US20250375498A1 (en) 2022-07-28 2025-12-11 The University Of Tokyo Neurotrimin function inhibitor
CN117031003A (zh) * 2023-07-25 2023-11-10 深圳市科曼医疗设备有限公司 醛固酮化学发光免疫检测试剂盒
WO2025202545A1 (en) * 2024-03-27 2025-10-02 Turun Yliopisto Immunocomplex antibodies and non-competitive immunoassay for the detection of testosterone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US5223441A (en) 1986-10-09 1993-06-29 Syntex (U.S.A.) Inc. Receptors for immune complexes
WO1995027045A1 (en) 1994-03-30 1995-10-12 Igen, Inc. The isolation and production of catalytic antibodies using phage technology
JP3025633B2 (ja) 1995-12-05 2000-03-27 株式会社蛋白工学研究所 グルタチオン結合活性を有するポリペプチド及びその製造方法
JP4228095B2 (ja) 1999-12-17 2009-02-25 東ソー株式会社 免疫測定方法および免疫測定試薬
CN1136450C (zh) * 2000-11-03 2004-01-28 厦门大学 具有荧光共振能量转移特征的成对蛋白及其用途

Also Published As

Publication number Publication date
EA200500643A1 (ru) 2005-12-29
US20060246506A1 (en) 2006-11-02
FI20022048A0 (fi) 2002-11-18
JP2006506634A (ja) 2006-02-23
NZ539714A (en) 2007-03-30
US7749712B2 (en) 2010-07-06
CA2503509C (en) 2013-02-05
EP1579222A1 (en) 2005-09-28
BRPI0316384B1 (pt) 2016-07-05
AU2003282143A1 (en) 2004-06-15
WO2004046733A1 (en) 2004-06-03
NO338417B1 (no) 2016-08-15
MXPA05005288A (es) 2005-08-16
DK1579222T3 (da) 2008-11-17
EP1579222B8 (en) 2009-01-07
CN1711476B (zh) 2010-09-08
ATE408146T1 (de) 2008-09-15
CA2503509A1 (en) 2004-06-03
JP4729701B2 (ja) 2011-07-20
BR0316384A (pt) 2005-10-04
ZA200503475B (en) 2006-07-26
NO20052849L (no) 2005-06-13
ES2312828T3 (es) 2009-03-01
EP1579222B1 (en) 2008-09-10
DE60323538D1 (de) 2008-10-23
CN1711476A (zh) 2005-12-21

Similar Documents

Publication Publication Date Title
BR0316384A (pt) Imunoensaio não competitivo para analitos pequenos
WO2002090983A3 (de) Quantitaver einschritt immuntest in lyophilisierter form
WO2007035633A3 (en) Screening assays and methods
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
DE502004011867D1 (de) Analytischer Sandwichtest zur Bestimmung von NT-proBNP
WO2005061547A3 (en) Bispecific antibodies
DE60222816D1 (de) Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
WO2007040559A3 (en) Electrochemiluminescent assay
WO2006102200A3 (en) Docetaxel immunoassay
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
EP1072888A3 (en) Immunoassay method and reagent for HIV-1p24 antigen
WO2006015098A3 (en) Taxol immunoassay
WO2006020263A3 (en) Cytoxan antibodies and immunoassay
ATE466884T1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
NO20052870D0 (no) Immunoanalysemetode og sett for anvendelse derav
WO2007054714A3 (en) Agglutination assay
ATE108907T1 (de) Bestimmungsverfahren, seine verwendung und komponenten.
NO903820L (no) Fremgangsmaate for paavisning av analytter.
ATE336513T1 (de) Antikörper, die spezifisch für freies inaktives psa sind, und ihre verwendungen
ATE437362T1 (de) Ig-assay
WO2006138694A3 (en) Rabbit monoclonal antibody against id1 protein
WO2007066231A3 (en) Rapid elisa
YU56001A (sh) Postupak semikvantitativne adsorpcije antitela prema blastokonidijama candida albicans

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2801 DE 10/09/2024 POR TER SIDO INDEVIDA.